Burgos, Alexander N

Subject: FW: [External] RE: NC Pharmacy Board Request for Changes - June 2022 RRC Meeting

From: Clint Pinyan < CPINYAN@brookspierce.com>

Sent: Monday, June 13, 2022 1:12 PM

To: Liebman, Brian R <bri> Sprian.liebman@oah.nc.gov>
 Cc: Burgos, Alexander N <alexander.burgos@oah.nc.gov>

Subject: RE: [External] RE: NC Pharmacy Board Request for Changes - June 2022 RRC Meeting

CAUTION: External email. Do not click links or open attachments unless you verify. Send all suspicious email as an attachment to Report Spam.

Dandy. Thanks so much. Please send them to Dana. I'll be on the Webex. (The only person who spoke at the public hearing was in favor of the changes, so I don't think anybody will show up to force me to talk.)

Clint Pinyan



t: 336.271.3157 f: 336.232.9157

2000 Renaissance Plaza 230 North Elm Street Greensboro, NC 27401 P.O. Box 26000 (27420)

From: Liebman, Brian R <bri> sprian.liebman@oah.nc.gov>

Sent: Monday, June 13, 2022 1:00 PM

To: Clint Pinyan < CPINYAN@brookspierce.com>

Cc: Burgos, Alexander N < alexander.burgos@oah.nc.gov>

Subject: RE: [External] RE: NC Pharmacy Board Request for Changes - June 2022 RRC Meeting

[EXTERNAL]

Clint,

Not a problem. Thanks for getting these out so soon after realizing.

I've reviewed your responses and revised rules, and I will recommend approval to RRC on Thursday. Unless I hear an objection, I'll send these over to Dana for filing.

Please let me know who from the agency will attend the meeting, and if they will attend in person or via Webex, so we can get an evite out to you.

Thanks, Brian

Brian Liebman
Counsel to the North Carolina Rules Review Commission
Office of Administrative Hearings
(984)236-1948
brian.liebman@oah.nc.gov

E-mail correspondence to and from this address may be subject to the North Carolina Public Records Law N.C.G.S. Chapter 132 and may be disclosed to third parties.

Burgos, Alexander N

Subject: FW: [External] RE: NC Pharmacy Board Request for Changes - June 2022 RRC Meeting

Attachments: Board of Pharmacy Response to Request for Changes 4894-6912-5413 v.1.docx; 21 NCAC 46 .2507

with technical changes 4890-1830-3525 v.1.docx; 21 NCAC 46 .1820 with technical changes 4874-8594-0773 v.1.docx; 21 NCAC 46 .2514 with technical changes 4855-9863-5557 v.1.docx

From: Clint Pinyan <CPINYAN@brookspierce.com>

Sent: Monday, June 13, 2022 11:54 AM

To: Liebman, Brian R <bri> Sprian.liebman@oah.nc.gov>
 Cc: Burgos, Alexander N <alexander.burgos@oah.nc.gov>

Subject: [External] RE: NC Pharmacy Board Request for Changes - June 2022 RRC Meeting

CAUTION: External email. Do not click links or open attachments unless you verify. Send all suspicious email as an attachment to Report Spam.

My responses and revisions attached. See if these answer all your questions. Sorry I missed the original e-mail.

Clint Pinyan



t: 336.271.3157 f: 336.232.9157

2000 Renaissance Plaza 230 North Elm Street Greensboro, NC 27401 P.O. Box 26000 (27420)

REQUEST FOR CHANGES PURSUANT TO G.S. 150B-21.10

AGENCY: North Carolina Board of Pharmacy

RULE CITATION: 21 NCAC 46 .1820

DEADLINE FOR RECEIPT: Friday, June 10, 2022.

<u>PLEASE NOTE:</u> This request may extend to several pages. Please be sure you have reached the end of the document.

The Rules Review Commission staff has completed its review of this Rule prior to the Commission's next meeting. The Commission has not yet reviewed this Rule and therefore there has not been a determination as to whether the Rule will be approved. You may email the reviewing attorney to inquire concerning the staff recommendation.

In reviewing this Rule, the staff recommends the following changes be made:

On lines 4-5, please consider conforming the incorporation by reference to our usual style, which uses "hereby incorporated" and states whether "all subsequent amendments or editions" are included.

Sorry. Tried to do it by memory. Fixed.

Also, I suggest swapping the final sentence regarding the availability of the Code with the second sentence, so that the incorporation by reference is contiguous.

Done.

Finally, because G.S. 150B-21.6 requires the agency to disclose the cost of the material (which here is free), please state that the Code is available online, free of charge.

Done.

On line 5, to be clear, it is the Board who is determining that conduct contrary to the Code is unprofessional, not the American Pharmacist Association?

Absolutely. This is like the State Bar copying the ABA rules (or any of a number of similar ethics codes that occupational licensing boards use). We will be applying it.

In your History Note, there are extra spaces between the hyphens and the section numbers for 90-85.22 and 90-85.44.

Fixed.

Also in the History Note, I think you need a reference to G.S. 90-85.38, for disciplinary authority.

Indeed.

Please retype the rule accordingly and resubmit it to our office at 1711 New Hope Church Road, Raleigh, North Carolina 27609.

REQUEST FOR CHANGES PURSUANT TO G.S. 150B-21.10

AGENCY: North Carolina Board of Pharmacy

RULE CITATION: 21 NCAC 46 .2507

DEADLINE FOR RECEIPT: Friday, June 10, 2022.

<u>PLEASE NOTE:</u> This request may extend to several pages. Please be sure you have reached the end of the document.

The Rules Review Commission staff has completed its review of this Rule prior to the Commission's next meeting. The Commission has not yet reviewed this Rule and therefore there has not been a determination as to whether the Rule will be approved. You may email the reviewing attorney to inquire concerning the staff recommendation.

In reviewing this Rule, the staff recommends the following changes be made:

In (b), line 7, I take it you are using "direct" to mirror the statutory language in G.S. 90-85.3(a)?

That is correct.

In (b)(1), line 8, what is "direct" here? Does your regulated public know?

The lawyer answer is that, since that's the term the General Assembly used, we have to use it, regardless. But the grammatical answer is that it means that the pharmacist has to be the one putting the drug on or in the body (unless he or she hands it to the patient, to do it as directed by the pharmacist). And the practical answer is that, as far as I know, current vaccines are all either shots or mists (like the flu mist). So, it means poking the patient or squirting the mist into the patient. It's intended to contrast with typical pharmacy dispensing, where you hand something to a patient and they drive off with it. The regulated people know.

HOWEVER, you ask a good question, and with respect to the provision for patient administration, I think some clarification is in order that you can't just hand the vaccine to the patient and then have the patient "directly apply it" at home. I've added some language. See if you think it makes it clearer.

In (b)(1)(A), lines 9-10, I think it would aid clarity if you broke subparagraph (A) into separate subparagraphs, such as suggested below:

- (A) an Immunizing Pharmacist;
- (B) a Pharmacy Intern or a registered pharmacy technician who is under the supervision of an Immunizing Pharmacist; or
- (B)(C) the patient at the direction of...

Good idea. Done.

In (c)(7), p.2, lines 26-27, would it change the meaning to simplify this sentence to say: "Makes an offer of counseling to the patient in compliance with Rule .2504 of this Section"?

It would change it only insofar as it would make it easier for people to understand it. Excellent change. Done. I don't know why I did it so strangely.

In (c)(8), lines 28-29, what does "designed to maintain competency" mean? Who decides what CE courses/topics meet this definition? Are these the same courses required by 90-85.15B(b1)?

Yes. This was intended to incorporate the statutory requirement and to put some meat on the bones about how often it should be taken. (The "how often" was taken from the federal declaration that currently allows technicians to vaccinate, so they've already been on that schedule.) But I've changed it to repeat the statutory phrase, to avoid confusion.

In (d), line 32, add the oxford comma after "Pharmacy Intern".

Done.

In (g)(1), p.3, line 10, delete "by" following "administered".

Done.

In (g)(1), line 11, what is "legal possession"? Does your regulated public know?

The usual legal and real world meaning: Whoever owns them, or otherwise has the rights of possession. Like other drugs, vaccines must be purchased and owned by people who have the legal authority to have them. That's either a pharmacy or a dispensing physician. The purpose of this provision is to say that – in addition to the normal situation where a pharmacist dispenses drugs owned by a pharmacy – a pharmacist or a technician could administer at a vaccination clinic at some doctor's office. But whoever has legal possession is the one who has to keep track of the drugs. In a world where pharmacy personnel have spent two years volunteering to give vaccines outside of pharmacies, they know how this works.

In (h)(1), line 24, what is "readily" retrievable? Does your regulated public know?

They know what it means. Virtually every reference to records in our rules require "readily" retrievable records. (See, e.g., .2607, which is the uber-rule about availability of records. But you can word search and see it used several times.) So, the point was to incorporate a standard that they already know.

In (h)(1), line 25, what are the "applicable rules and statute"? Does your regulated public know?

They would be the statute and the rules governing maintenance of pharmacy records, for example .2607, cited above. The point of this general reference was to suggest that the normally used records retention rules apply. We have never had an issue with anyone not knowing that they need to keep these records in the same way they keep any other drug records.

In (i), p.4, lines 5-6, I understand the Immunizing Pharmacist will maintain the policies, but will he or she also write them or is there a set of policies that he or she will use?

We don't nitpick people's policies, so long as they have them. That's a common theme in our rules – you come up with a policy that fits your circumstances. In this case, since it's dealing with used needles (essentially), I'm gonna guess they'll develop them from OSHA guidelines.

Please retype the rule accordingly and resubmit it to our office at 1711 New Hope Church Road, Raleigh, North Carolina 27609.

REQUEST FOR CHANGES PURSUANT TO G.S. 150B-21.10

AGENCY: North Carolina Board of Pharmacy

RULE CITATION: 21 NCAC 46 .2514

DEADLINE FOR RECEIPT: Friday, June 10, 2022.

<u>PLEASE NOTE:</u> This request may extend to several pages. Please be sure you have reached the end of the document.

The Rules Review Commission staff has completed its review of this Rule prior to the Commission's next meeting. The Commission has not yet reviewed this Rule and therefore there has not been a determination as to whether the Rule will be approved. You may email the reviewing attorney to inquire concerning the staff recommendation.

In reviewing this Rule, the staff recommends the following changes be made:

In (b), line 7, I take it you are using "direct" to mirror the statutory language in G.S. 90-85.3(a)?

That's a fact. As you have surmised, to the extent possible, we copied these from the vaccination rules, so that people would know to do the same thing that they've been doing for years with respect to vaccines. So, my answers are all pretty much the same as in .2507. In this case, we defined "administer" to include just administration by injection, since that's all this rule covers.

In (b)(1), line 8, what is "direct" here? Does your regulated public know?

See the answers for .2507, and I've made the same clarifying change, to keep .2514 consistent with .2507

In (b)(1), lines 8-9, I think it would aid clarity if you broke subparagraph (1) into separate subparagraphs, such as suggested below:

- (1) an Immunizing Pharmacist;
- (2) a Pharmacy Intern or a registered pharmacy technician who is under the supervision of an Immunizing Pharmacist; or
- (2)(3) the patient at the direction of...

Made these changes and made them consistent with .2507 (except that pharmacy techs can't administer LAIs, unlike vaccines).

In (f)(1), line 29, what is "legal possession"? Does your regulated public know?

Same answer as .2507

In (g)(1), p.2, line 7, what is "readily" retrievable? Does your regulated public know?

Same answer as .2507.

In (g)(1), line 8, what are the "applicable rules and statute"? Does your regulated public know?

Same answer as .2507.

In (h), lines 20-21, I understand the Immunizing Pharmacist will maintain the policies, but will he or she also write them or is there a set of policies that he or she will use?

Same answer as .2507.

Please retype the rule accordingly and resubmit it to our office at 1711 New Hope Church Road, Raleigh, North Carolina 27609.

1	21 NCAC 46 .1820 is adopted with changes as published in 36:16 NCR 1390 as follows:
2	
3	21 NCAC 46 .1820 CODE OF ETHICS
4	All pharmacists must comply with the American Pharmacist Association Code of Ethics, which is hereby incorporate
5	[herein] by reference, along with all subsequent amendments or editions. [to that Code of Ethics.] A copy of the Cod
6	of Ethics is available free of charge on the Board's website at http://ncbop.org/lawandrules.htm. Any contrary conductions of the contrary conduction of the
7	is unprofessional conduct under G.S. 90-85.38. [A copy of the Code of Ethics is available on the Board's website
8	http://nebop.org/lawandrules.htm.]
9	
10	History Note: Authority G.S. 90-85.3A; 90-85.6; 90-85.15A; 90-85.15B; [90-85.22;]-90-85.22; 90-85.26; 90
11	85.26A; 90-85.32; 90-85.33; 90-85.34 <mark>; 90-85.38; [90-85.44;] 90-85.44;</mark> S.L. 2021-110, s. 4.(a):
12	Eff. July 1, 2022.

1	21 NCAC 46 .25	507 is amended with changes as published in 36:16 NCR 1390 as follows:
2		
3	21 NCAC 46 .25	
4		ting Pharmacist shall administer only those vaccines or immunizations permitted by G.S. 90-85.15E
5		ubject to all requirements of that statute and this Rule.
6		ng words and terms, when used in this Rule, have the following meanings:
7	(1)	"Administer" means the direct application of a drug to the body of a patient by injection, inhalation
8		ingestion, or other means by:
9		(A) an Immunizing Pharmacist or Pharmacist;
10		(B) a Pharmacy Intern or registered pharmacy technician who is under the direct, in persor
11		supervision of an Immunizing Pharmacist; or
12		(B)(C) the patient at the direction and under the direct, in-person supervision of either are
13		Immunizing Pharmacist or a health care provider authorized by North Carolina law to
14	(2)	prescribe the vaccine.
15	(2)	"Immunizing Pharmacist" shall have the meaning provided in G.S. 90-85.3(i1).
16	(3)	"Immunizing Pharmacy Personnel" means an Immunizing Pharmacist, or a Pharmacy Intern or a
17		registered pharmacy technician who administers vaccines under the supervision of an Immunizing
18	(2) (4)	Pharmacist.
19	(3)(4)	"Pharmacy Intern" shall have the meaning provided in 21 NCAC 46 .1317(29).
20	(4) (5)	"Physician" means an M.D. or D.O. currently licensed with the North Carolina Medical Board who
21		is responsible for the supervision of the Immunizing Pharmacist pursuant to the Written Protoco
22		between the Immunizing Pharmacist and the Physician.
23	(6)	RESERVED
24	(7)	RESERVED
25	(8)	RESERVED
26	(9)	RESERVED
27	(10)	RESERVED
28	(11)	RESERVED
29	(12)	"Written Protocol" is a document prepared, signed, and dated by the Physician and Immunizing
30		Pharmacist that shall contain the following:
31		(A) the name of the Physician responsible for authorizing the Written Protocol;
32		(B) the name of the Immunizing Pharmacist authorized to administer vaccines;
33		(C) the immunizations or vaccinations that may be administered by the Immunizing
34		Pharmacist;
35		(D) the screening questionnaires and safety procedures that shall at least include the then-
36		current minimum standard screening questionnaire and safety procedures adopted by the
37		Medical Board, the Board of Nursing, and the Board of Pharmacy pursuant to S.L. 2013-

1

1		246, s. 6, and available at the Board of Pharmacy's office and on its website
2		(www.ncbop.org).
3		(E) the procedures to follow, including any drugs required by the Immunizing Pharmacist for
4		treatment of the patient, in the event of an emergency or adverse event following vaccine
5		administration;
6		(F) the reporting requirements by the Immunizing Pharmacist to the Physician, including
7		content and time frame; and
8		(G) the locations at which the Immunizing Pharmacist may administer immunizations or
9		vaccinations.
10	The Physician	and the Immunizing Pharmacist shall review the Written Protocol at least annually and revise it if
11	necessary.	
12	(c) A registere	d pharmacy technician may administer those vaccines or immunizations permitted by G.S. 90-85.15B
13	on behalf of an	Immunizing Pharmacist, if the registered pharmacy technician does the following:
14	<u>(1)</u>	Completes a practical training program that is approved by the Accreditation Council of Pharmacy
15		Education:
16	<u>(2)</u>	Holds a current basic CPR certification;
17	<u>(3)</u>	Notifies the North Carolina Board of Pharmacy of immunizing pharmacy technician status;
18	<u>(4)</u>	Is supervised by an Immunizing Pharmacist who is responsible for ensuring compliance with all
19		legal requirements for vaccinations administered by a registered pharmacy technician under this
20		Rule:
21	<u>(5)</u>	Either (i) has an Immunizing Pharmacist on site and readily available to assist as needed, or (ii) has
22		another licensed health care provider authorized to administer vaccines on site and readily available
23		to assist as needed and has a supervising pharmacist readily available by phone or other
24		telecommunications method for consultation as needed;
25	<u>(6)</u>	Has the Immunizing Pharmacist or other health care provider who is present under Subparagraph
26		(5) of this Paragraph review the patient's vaccine registry or other vaccination records and the
27		screening questionnaire before the pharmacy technician administers the vaccine;
28	<u>(7)</u>	Makes an offer of counseling to the spatient, which offer to counsel and any counseling should
29		comply in compliance with Rule .2504 of this Section; and
30	<u>(8)</u>	Maintains documentation of three hours of immunization-related continuing education approved by
31		the Accreditation Council for Pharmacy Education every two years. [years, designed to maintain
32		competency in vaccine administration.]
33	(c)(d) An Imm	unizing Pharmacy Personnel Pharmacist who, because of physical disability, is are unable to obtain a
34	current provide	r level CPR certification pursuant to G.S. 90-85.3(i1)(1), may administer vaccines in the presence of a
35	pharmacy techn	nician, Pharmacy Intern, [Intern] technician or pharmacist who holds a current provider level CPR
36	certification.	

JUNE 13, 2022 4890-1830-3525.v1

1	(d)(e) With each	ch dose of vaccine, either the Immunizing <u>Pharmacy Personnel</u> Pharmacist or a Pharmacy Intern sha	all	
2	give the most current vaccine information regarding the purpose, risks, benefits, and contraindications of the vaccin			
3	to the patient or legal representative. The Immunizing Pharmacy Personnel Pharmacist or Pharmacy Intern must ensure			
4	that the patient	that the patient or legal representative has the opportunity to read, or to have read to him or her, the information		
5	provided and to	have any questions answered prior to administration of the vaccine.		
6	(e)(f) In agreei	ng to serve as a supervising Physician, the Physician shall agree to meet the following requirements	:	
7	(1)	be responsible for the formulation or approval of the Written Protocol and review the Written	en	
8		Protocol and the services provided to patients under the Written Protocol, as set out in Subparagrap	рh	
9		(b)(12) of this Rule;		
10	(2)	be accessible to the Immunizing Pharmacist or be available through direct telecommunication for	or	
11		consultation, assistance, direction, and provide back-up coverage; and		
12	(3)	receive periodic status reports from the Immunizing Pharmacist, including any problems	or	
13		complications encountered.		
14	(f)(g) The follo	owing requirements pertain to drugs administered by an Immunizing Pharmacy Personnel: Pharmacis	st:	
15	(1)	Drugs administered by an Immunizing Pharmacist under the provisions of this Rule shall be in the	ne	
16		legal possession of:		
17		(A) a pharmacy, which shall be the pharmacy responsible for drug accountability, including	ng	
18		the maintenance of records of administration of the immunization or vaccination; or		
19		(B) the Physician, who shall be responsible for drug accountability, including the maintenance	ce	
20		of records of administration of the immunization or vaccination;		
21	(2)	Drugs shall be transported and stored at the proper temperatures indicated for each drug;		
22	(3)	Immunizing Pharmacy Personnel, Pharmacists, while engaged in the administration of vaccine	es	
23		under the Written Protocol, shall have in their custody and control the vaccines identified in the	ne	
24		Written Protocol and any other drugs listed in the Written Protocol to treat adverse events; and		
25	(4)	After administering vaccines at a location other than a pharmacy, the Immunizing Pharmacy	сy	
26		Personnel Pharmacist shall return all unused prescription medications to the pharmacy or Physicia	an	
27	responsible for the drugs.			
28	(g)(h) Record Keeping and Reporting.			
29	(1)	An Immunizing Pharmacist shall maintain the following information, readily retrievable, in the	he	
30		pharmacy records in accordance with the applicable rules and statute regarding each administration	n:	
31		(A) the name, address, and date of birth of the patient;		
32		(B) the date of the administration;		
33		(C) the administration site of injection (e.g., right arm, left leg, right upper arm);		
34		(D) route of administration of the vaccine;		
35		(E) the name, manufacturer, lot number, and expiration date of the vaccine;		
36		(F) dose administered;		

JUNE 13, 2022 4890-1830-3525.v1

1		(G) the name and address of the patient's primary health care provider, as identified by the		
2		patient; and		
3		(H) the name or identifiable initials of the Immunizing Pharmacist.		
4	(2)	An Immunizing Pharmacist shall document the annual review with the Physician of the Written		
5		Protocol as required in this Rule.		
6	(3)	An Immunizing Pharmacist shall report adverse events associated with administration of a vaccine		
7		to either the prescriber, when administering a vaccine pursuant to G.S. 90-85.15B(a), or the patient's		
8		primary care provider, if the patient identifies one, when administering a vaccine pursuant to G.S.		
9		90-85.15B(b).		
10	(h)(i) The Immunizing Pharmacist shall maintain written policies and procedures for handling and disposal of used			
11	or contaminated equipment and supplies.			
12	(j) The Immunizing Pharmacist shall comply with Rule .1820 of this Chapter in the practice of pharmacy pursuant to			
13	this Rule.			
14				
15				
16				
17	History Note:	Authority G.S. 90-85.3; 90-85.6; 90-85.15B; S.L. 2021-110, s. 4.(a) and (b):		
18		Eff. April 1, 2003;		
19		Emergency Amendment Eff. May 11, 2004;		
20		Temporary Amendment approved by RRC October 21, 2004;		
21		Amended Eff. February 1, 2008; November 1, 2005; November 1, 2004;		
22		Emergency Amendment Eff. October 9, 2009;		
23		Temporary Amendment Eff. December 29, 2009;		
24		Amended Eff. September 1, 2014; March 1, 2012;		
25		Pursuant to G.S. 150B-21.3A, rule is necessary without substantive public interest Eff. October 3,		
26		2017;		
27		Amended Eff. June 1, 2020. 2020; July 1, 2022.		

1	21 NCAC 46 .2514 is adopted with changes as published in 36:16 NCR 1393 as follows:		
2			
3	21 NCAC 46 .2514 ADMINISTRATION OF LONG-ACTING INJECTABLES		
4	(a) A "long-ac	ting injec	table" is drug product formulated to produce sustained release and gradual absorption of the
5	active pharma	ceutical i	ingredient over an extended period of time after administration by subcutaneous or
6	intramuscular i	njection.	
7	(b) "Administe	r" means	the direct application of a drug to the body of a patient by injection by:
8	<u>(1)</u>	an Imr	nunizing Pharmacist or <u>Pharmacist;</u>
9	<u>(2)</u>	a phar	macy intern who is under the direct, in-person supervision of an Immunizing Pharmacist; or
10	(2) (3)	the par	tient at the direction and under the direct, in-person supervision of either an Immunizing
11		Pharm:	acist or a health care provider authorized by North Carolina law to prescribe the long-acting
12		injecta	ble.
13	(c) In order to	<u>administe</u>	er long-acting injectables, an Immunizing Pharmacist must:
14	<u>(1)</u>	satisfy	all requirements to be an "Immunizing Pharmacist" under G.S. 90-85.3(i1);
15	<u>(2)</u>	docum	ent training on administering long-acting injectables both subcutaneously and
16		<u>intram</u>	uscularly. This training may include a program accredited by the American Council on
17		<u>Pharm</u>	aceutical Education (ACPE) or the North Carolina Association of Pharmacists, curriculum
18		based	programs from an ACPE-accredited school of pharmacy, state or local health department
19		progra	ms, or training by a health care practitioner with experience in administering long-acting
20		injecta	bles;
21	<u>(3)</u>	notify	the Board of the status as both an Immunizing Pharmacist and a pharmacist who administers
22		long-a	cting injectables; and
23	<u>(4)</u>	<u>admini</u>	ister long-acting injectables in accordance with G.S. 90-85.15B, as well as all other pertinent
24		State 3	and federal laws and regulations (including but not limited to U.S. Food and Drug
25		Admin	nistration Risk Evaluation and Mitigation Strategies).
26	(d) An Immun	izing Pha	rmacist who, because of physical disability, is unable to obtain a current provider level CPR
27	certification pu	rsuant to	G.S. 90-85.3(i1)(1), may administer long-acting injectables in the presence of a pharmacy
28	technician or pl	<u>ıarmacist</u>	who holds a current provider level CPR certification.
29	(e) Before ea	ich admir	nistration of a long-acting injectable, the Immunizing Pharmacist must personally and
30	affirmatively co	onduct pa	tient counseling that complies with Rule .2504 of this Chapter.
31	(f) The following	ng requir	ements pertain to long-acting injectables administered by an Immunizing Pharmacist:
32	<u>(1)</u>	<u>Drugs</u>	administered by an Immunizing Pharmacist under the provisions of this Rule shall be in the
33		<u>legal p</u>	ossession of:
34		<u>(A)</u>	a pharmacy, which shall be the pharmacy responsible for drug accountability, including
35			the maintenance of records of administration of the long-acting injectable; or
36		<u>(B)</u>	a prescriber, who shall be responsible for drug accountability, including the maintenance
37			of records of administration of the long-acting injectable.

1

1	<u>(2)</u>	Drugs shall be transported and stored at the proper temperatures indicated for each drug.		
2	<u>(3)</u>	Immunizing Pharmacists, while engaged in the administration of long-acting injectables, shall have		
3		in their custody and control drugs needed to treat adverse events.		
4	<u>(4)</u>	After administering long-acting injectables at a location other than a pharmacy, the Immunizing		
5		Pharmacist shall return all unused prescription medications to the pharmacy or prescriber		
6		responsible for the drugs.		
7	(g) Record Kee	ping and Reporting.		
8	<u>(1)</u>	An Immunizing Pharmacist shall maintain the following information, readily retrievable, in the		
9		pharmacy records in accordance with the applicable rules and statute regarding each administration		
10		of a long-acting injectable:		
11		(A) the name, address, and date of birth of the patient;		
12		(B) the date of the administration;		
13		(C) the administration site of injection (e.g., right arm, left leg, right upper arm);		
14		(D) route of administration of the drug;		
15		(E) the name, manufacturer, lot number, and expiration date of the drug;		
16		(F) dose administered;		
17		(G) the name and address of the prescriber; and		
18		(H) the name or identifiable initials of the Immunizing Pharmacist.		
19	<u>(2)</u>	An Immunizing Pharmacist shall report to the prescriber adverse events associated with		
20		administration of a long-acting injectable.		
21	(h) The Immunizing Pharmacist shall maintain written policies and procedures for handling and disposal of used			
22	contaminated equipment and supplies.			
23				
24	<u>History Note:</u>	Authority G.S. 90-85.3; 90-85.6; 90-85.15B;		
25		Eff. July 1, 2022.		

Burgos, Alexander N

From: Liebman, Brian R

Sent: Friday, June 3, 2022 9:59 AM

To: Clint Pinyan

Cc: Burgos, Alexander N

Subject: NC Pharmacy Board Request for Changes - June 2022 RRC Meeting

Attachments: 06.2022 - Board of Pharmacy Request for Changes.docx

Hi Clint,

I'm the attorney who reviewed the Rules submitted by the Pharmacy Board for the June 2022 RRC meeting. The RRC will formally review these Rules at its meeting on Thursday, June 16, 2022, at 9:00 a.m. The meeting will be a hybrid of in-person and WebEx attendance, and an evite should be sent to you as we get closer to the meeting. If there are any other representatives from your agency who will want to attend virtually, let me know prior to the meeting, and we will get evites out to them as well.

Please submit the revised Rules and forms to me via email, no later than 5 p.m. on Friday, June 10, 2022. You'll note that some of my questions/requests are taken from Amanda's tech change requests from the temp rules that these rules are replacing; I either also had the same question or felt it would be beneficial for RRC to see the answer again.

In the meantime, please do not hesitate to reach out via email with any questions or concerns.

Thanks,

Brian

Brian Liebman
Counsel to the North Carolina Rules Review Commission
Office of Administrative Hearings
(984)236-1948
brian.liebman@oah.nc.gov

E-mail correspondence to and from this address may be subject to the North Carolina Public Records Law N.C.G.S. Chapter 132 and may be disclosed to third parties.

Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to third parties by an authorized state official.